Receive Our Newsletter

Industry News

CSL Behring Presents Phase 3 Data about Afstyla for Hemophilia A

Note: The below is an edited version of an article originally published on PR Newswire. The original release can be read in it’s entirety here. CSL Behring today presented data from a Phase III pivotal study of Afstyla [Antihemophilic Factor (Recombinant), Single Chain] in hemophilia A patients less than 12 years of age at the XXXII International Congress […]

medical_news_600x600

Voluntary Withdrawals of Helixate FS & Kogenate FS

As part of HFA’s ongoing mission to assist and advocate for the bleeding disorders community, this medical news is being issued to keep you informed about product safety. About These Withdrawals CSL Behring is initiating a voluntarily recall of two lots of its hemophilia A drug Helixate FS containing active ingredient manufactured before November 2015. […]

Industry News

Adynovate Phase 3 Efficacy and Safety Data in Children to be Presented

Note: The below is an edited version of an article originally published on PR Newswire. The original release can be read in it’s entirety here. _________________________________________________________________________________________ Shire will present additional data on the clinical experience of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended half-life recombinant Factor VIII (rFVIII) replacement for hemophilia A, during the International […]

Industry News

CSL Behring Presents Phase III Data for IDELVION for Hemophilia B

Note: The below is an edited version of an article originally published on Yahoo Finance. The original release can be read in it’s entirety here. _________________________________________________________________________________________ CSL Behring announced new data today from its Phase III PROLONG-9FP clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s long-acting recombinant albumin fusion protein […]

Industry News

Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran

Note: The below is an edited version of an article originally published on StreetInsider.com. The original release can be read in it’s entirety here. _________________________________________________________________________________________ Alnylam Pharmaceuticals, Inc. announced today new positive results from its ongoing Phase 1 study with Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B and […]

Carrie_blog_2016-07-27

Infusing Love: Defining Normal

“How do you do it?” “Isn’t it difficult?” “Do you feel as though you need to wrap him in bubble wrap?” “How do you handle all of it?” Most bleeding disorders moms have had to answer those questions or something similar to them. Questions of that nature do not surprise me anymore, because what parenting […]

Industry News

Novo Nordisk Announces New Data on Psychosocial Impact of People Living with Hemophilia B

Note: The below is an edited version of a press release by Novo Nordisk. The original release can be read in it’s entirety here.  Novo Nordisk today announced the first results from the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) study, which found that many adults and children living with even mild or […]

funny_bone_dear_addy[1]

Dear Addy: Joint Replacement Surgery

Dear Addy, I’m a 50-year-old with hemophilia A, who’s right elbow has seen better days. I’m in the process of researching all my surgical options before making an appointment with my HTC. At this point in my life I’m really intrigued with an elbow replacement. Do you know of any other results throughout the community? […]

Industry News

Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B

Note: The below is an edited version of a press release by Spark Therapeutics. The original release can be read in it’s entirety here. Spark Therapeutics and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to SPK-9001, the lead investigational candidate in the companies’ SPK-FIX program, in development for the treatment of hemophilia B. SPK-9001, a […]

HFALogoGlow

HFA to Present CHOICE Project Data at World Federation of Hemophilia World Congress

HFA to Present CHOICE Project Data at World Federation of Hemophilia World Congress  The CHOICE Project was a first-of-its-kind data collection from people with hemophilia and other bleeding disorders. FOR IMMEDIATE RELEASE: July 21, 2016 Contact: Sonji Wilkes (202)-675-6984 or email at s.wilkes@hemophiliafed.org Hemophilia Federation of America (HFA) announced today that it will present new […]

Page 1 of 12512345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community